ReviewCell host & microbe2013
Antibody-mediated immunity against tuberculosis: implications for vaccine development.
Review in Cell host & microbe, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 178 citations in OpenAlex.
- Trial
- Latently and uninfected healthcare workers exposed to TB make protective antibodies againstProceedings of the National Academy of Sciences of the United States of America · 2017Trial
- A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Medicine · 2016Trial
- Trial
- Current perspectives on avian tuberculosis in domestic and wild birds: Molecular diagnostics, genomic surveillance, and vaccination challenges.Open veterinary journal · 2026Review
- Host-directed broad-spectrum immunotherapeutic strategy for respiratory infections: Heat-killed Caulobacter crescentus (HKCC) as an innate-immune based biotherapeutic/postbiotic.PLoS pathogens · 2026Article
- Peripheral blood B-cell compartment dysregulation in multidrug-resistant tuberculosis is associated with reduced circulating marginal zone-like B cells.Frontiers in immunology · 2026Article
- Monoclonal Antibodies Targeting Bacillus Calmette-Guérin (BCG) Outer Membrane Proteins Confer Protection Against Tuberculosis.Transboundary and emerging diseases · 2026Article
- Identification and serological characterization of MtbAg1073, a conserved Mycobacterium tuberculosis complex antigen recognized in active tuberculosis.Environmental health and preventive medicine · 2026Article
- A proteome-wide atlas of humoral immunity toFrontiers in immunology · 2026Article
- Novel Multistage SubunitVaccines · 2025Article
- Article
- A comprehensive analysis of magnetic resonance imaging and laboratory features in pyogenic, tuberculous, brucellar, and fungal spondylitis.Quantitative imaging in medicine and surgery · 2025Article
- Tertiary Lymphoid Structures in Tuberculosis: Persistence, Protection, and Pathology.Immunological reviews · 2025Review
- A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis.Cell communication and signaling : CCS · 2025Article
- A subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice.iScience · 2025Article
- CD39 dynamics in tuberculosis: a potential biomarker of immune dysregulation and T cell exhaustion.Frontiers in immunology · 2025Article
- Therapeutic vaccination with the Ag85B-Rv2660c-MPT70 fusion protein enhancesFrontiers in immunology · 2025Article
- A multi-epitope vaccine incorporating adhesin-derived antigens protects againstFrontiers in immunology · 2025Article
- Humoral correlate of vaccine-mediated protection from tuberculosis identified in humans and non-human primates.bioRxiv : the preprint server for biology · 2024Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.